Your browser doesn't support javascript.
loading
Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas.
Liebers, Nora; Duell, Johannes; Fitzgerald, Donnacha; Kerkhoff, Andrea; Noerenberg, Daniel; Kaebisch, Eva; Acker, Fabian; Fuhrmann, Stephan; Leng, Corinna; Welslau, Manfred; Chemnitz, Jens; Middeke, Jan-Moritz; Weber, Thomas; Holtick, Udo; Trappe, Ralf; Pfannes, Roald; Liersch, Ruediger; Spoer, Christian; Fuxius, Stefan; Gebauer, Niklas; Caillé, Léandra; Geer, Thomas; Koenecke, Christian; Keller, Ulrich; Claus, Rainer; Mougiakakos, Dimitrios; Mayer, Stephanie; Huettmann, Andreas; Pott, Christiane; Trummer, Arne; Wulf, Gerald; Brunnberg, Uta; Bullinger, Lars; Hess, Georg; Mueller-Tidow, Carsten; Glass, Bertram; Lenz, Georg; Dreger, Peter; Dietrich, Sascha.
Afiliação
  • Liebers N; Department of Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
  • Duell J; National Center for Tumor Diseases Heidelberg, Heidelberg, Germany.
  • Fitzgerald D; Department of Internal Medicine II, Würzburg University Hospital, University of Würzburg, Würzburg, Germany.
  • Kerkhoff A; Department of Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
  • Noerenberg D; European Molecular Biology Laboratory, Heidelberg, Germany.
  • Kaebisch E; Department of Medicine A, University Hospital Münster, Münster, Germany.
  • Acker F; Department of Hematology, Oncology and Tumor Immunology (Campus Virchow-Klinikum), Charité University Medicine, Berlin, Germany.
  • Fuhrmann S; Department of Hematology, Oncology and Tumor Immunology (Campus Virchow-Klinikum), Charité University Medicine, Berlin, Germany.
  • Leng C; Department of Medicine 2, Hematology and Oncology, University Hospital Frankfurt, Frankfurt, Germany.
  • Welslau M; Department of Hematology, HELIOS Klinikum Berlin-Buch, Berlin, Germany.
  • Chemnitz J; Department of Hematology, Oncology, and Tumor Immunology (Campus Benjamin Franklin), Charité University Medicine, Berlin, Germany.
  • Middeke JM; MVZ am Klinikum Aschaffenburg, Onkologie und Hämatologie, Aschaffenburg, Germany.
  • Weber T; Gemeinschaftsklinikum Mittelrhein GmbH, Koblenz, Germany.
  • Holtick U; University Hospital Dresden, Dresden, Germany.
  • Trappe R; Department of Medicine IV, Hematology and Oncology, University of Halle, Halle, Germany.
  • Pfannes R; Department I of Internal Medicine, Medical Faculty and University Hospital, Cologne, University of Cologne, Cologne, Germany.
  • Liersch R; Department of Hematology and Oncology, DIAKO Ev. Diakonie-Krankenhaus Bremen, Bremen, Germany.
  • Spoer C; Department of Medicine I, Städtisches Klinikum Dessau, Dessau, Germany.
  • Fuxius S; Praxis Medical Center, Gemeinschaftspraxis für Hämatologie und Onkologie Münster, Münster, Germany.
  • Gebauer N; MVZ am EVK Düsseldorf, Internistische Onkologie und Hämatologie, Düsseldorf, Germany.
  • Caillé L; Onkologische Schwerpunktpraxis Heidelberg, Heidelberg, Germany.
  • Geer T; Department of Haematology and Oncology, University Hospital of Schleswig-Holstein, Campus Lübeck, Germany.
  • Koenecke C; Department of Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
  • Keller U; Diakonie Klinikum Schwäbisch-Hall, Innere Medizin III, Schwäbisch Hall, Germany.
  • Claus R; Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.
  • Mougiakakos D; Department of Hematology, Oncology, and Tumor Immunology (Campus Benjamin Franklin), Charité University Medicine, Berlin, Germany.
  • Mayer S; Hematology and Oncology, Medical Faculty, University of Augsburg, Augsburg, Germany.
  • Huettmann A; Department of Internal Medicine 5, Hematology and Clinical Oncology, Friedrich-Alexander University (FAU) of Erlangen-Nuremberg, Erlangen, Germany.
  • Pott C; Department of Internal Medicine III, University Hospital of Regensburg, Regensburg, Germany.
  • Trummer A; Department of Hematology, University Hospital of Essen, Essen, Germany.
  • Wulf G; Second Medical Department, University Hospital Schleswig-Holstein, Campus Kiel, Germany.
  • Brunnberg U; Department of Hematology and Oncology, Klinikum Braunschweig, Braunschweig, Germany.
  • Bullinger L; Clinic for Hematology and Medical Oncology, University Medicine Göttingen, Germany; and.
  • Hess G; Department of Medicine 2, Hematology and Oncology, University Hospital Frankfurt, Frankfurt, Germany.
  • Mueller-Tidow C; Department of Hematology, Oncology and Tumor Immunology (Campus Virchow-Klinikum), Charité University Medicine, Berlin, Germany.
  • Glass B; Department of Hematology, Oncology and Pneumology, Johannes Gutenberg-University, Mainz, Germany.
  • Lenz G; Department of Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
  • Dreger P; National Center for Tumor Diseases Heidelberg, Heidelberg, Germany.
  • Dietrich S; Department of Hematology, HELIOS Klinikum Berlin-Buch, Berlin, Germany.
Blood Adv ; 5(13): 2707-2716, 2021 07 13.
Article em En | MEDLINE | ID: mdl-34196677
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article